TAVR in Nonagenarians

Analysis of a national registry of transcatheter aortic valve replacement in nonagenarians demonstrates safety and efficacy in selected patients.

Invasive and/or expensive interventions in the very elderly are controversial. Researchers used the national Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry and Medicare data to compare outcomes of transcatheter aortic valve replacement (TAVR) in 3773 patients aged ≥90 (median age, 92; 16% of registry population) and 20,252 patients aged <90 (median age, 82).

All were treated with commercial devices. The nonagenarians were more liable to be female and to have fewer comorbidities than the younger patients, including diabetes, prior cardiac surgery, stroke, and myocardial infarction.

In-hospital complications were significantly higher in the nonagenarians than in the younger patients, including r…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)